Skip to content
A gloved hand operating a manual filling station for small vials inside a sterile stainless steel isolator (spectra M1 from SKAN), with a precise needle mechanism for liquid dispensing.

Overcoming the challenges of low-volume manufacturing

Ensuring sterility, maximizing product yield, and maintaining manufacturing flexibility for high-value biopharmaceutical products

Learn more
Applications

The products that are manufactured in small batches

  • Products in clinical phases

    From Phase I to Phase III

  • Orphan drugs

    Therapies targeting rare diseases

  • Cell & gene therapies

    Allogeneic and autologous therapies

  • Biologics

    Complex therapies derived from living systems

Why small-batch manufacturing matters

The past few years have seen an increase in approved specialized therapies such as cell and gene therapies (as of early 2026, 46 C&G therapies have been approved by the FDA), personalized medicine, orphan drugs (97 approved in 2025 by the FDA, and 837 since 2017), and other novel therapies. These drugs require much smaller batches than traditional medicine.

We often refer to batches of fewer than 5,000 units as small batches, but some advanced therapy batches yield even fewer units, right down to one final unit for some autologous therapies.

With such small batches and high value, every dose matters. Traditional high-throughput manufacturing facilities are not adapted to the challenges that small-batch manufacturing poses. As batch sizes decrease, the impact of contamination events, product loss, and operational inefficiencies increases significantly.

Key challenges

The realities of small-batch manufacturing

  • Maintaining sterility

    Small-batch manufacturing must meet the same stringent GMP and sterility requirements as large-scale production. At the same time, more frequent manual interventions can increase contamination risks and compromise aseptic integrity.

  • Manufacturing flexibility

    Small-batch facilities must frequently switch between products, formats, and production campaigns. This requires flexible equipment that supports rapid changeovers while keeping pace with demanding development and supply timelines.

  • Cost and time efficiency

    Traditional high-speed filling lines are often oversized for small-batch production. Efficient manufacturing requires right-sized equipment, reduced downtime, and a compact footprint that fits flexible manufacturing environments.

  • Every milliliter matters

    High-value biologics and advanced therapies are often manufactured in limited quantities, making product preservation a critical objective. Even minor losses can significantly impact yield, manufacturing costs, and product availability.

Compliance

Maximizing sterility assurance in small-batch fill & finish

When product volumes decrease and product value increases, the consequences of contamination become significantly greater. In small-batch aseptic fill & finish, a single contamination event can compromise an entire manufacturing campaign, making robust sterility assurance a critical success factor.

The fill & finish strategy therefore plays a central role in contamination control. At SKAN, sterility assurance is built around isolator technologies, automation, and closed processing concepts designed to minimize operator interventions, one of the primary sources of contamination risk in aseptic manufacturing. By reducing the need for manual manipulation and maintaining separation between operators and critical process zones, these technologies contribute to a more controlled and reproducible aseptic environment.

Closed container processes and single-use assemblies further support sterility assurance by maintaining product protection throughout the filling operation while reducing opportunities for environmental exposure.

Beyond equipment and process design, sterility assurance relies on a comprehensive quality framework. SKAN systems are supported by documentation and validation packages developed to facilitate compliance with global regulatory expectations. Manufacturing processes should be developed, validated, and executed in accordance with cGMP requirements, with documentation aligned to FDA, EMA, and PIC/S expectations. Robust validation packages, environmental monitoring strategies, and contamination control measures help ensure readiness for regulatory submissions, inspections, and ongoing commercial production.

Flexibility and efficiency

Accommodating multiple products, batch sizes, and container formats while minimizing downtime

  • Inside chamber of the Cellana XL1 system.

    Process adaptability

    Fill & finish equipment should be adaptable to specific product requirements and production volumes, from small clinical batches to mid-scale commercial manufacturing. Modular configurations support a wide range of container formats, including vials, syringes, and cartridges, helping manufacturers respond quickly to evolving needs.

  • Cellana L1 automated filling with LAF application.

    Easy facility integration

    To remain economically viable, small-batch filling systems should also offer a compact footprint and straightforward implementation, enabling integration into existing facilities without the complexity and infrastructure requirements often associated with large-scale production equipment.

  • A close-up of a stainless steel "skanfog" decontamination nozzle integrated into a sterile enclosure. The circular metal component is flush-mounted against a smooth, industrial surface, designed for H2O2 fogging in cleanroom environments.

    Rapid changeover and decontamination

    Frequent product changeovers can significantly impact productivity. Fast format changes, simplified setup procedures, and efficient H₂O₂ decontamination cycles help reduce downtime and maximize equipment utilization, making them particularly valuable in multi-product facilities and flexible manufacturing environments.

Protection

Preserving valuable product

For high-value biologics, cell therapies, and gene therapies, preserving the product is just as important as maintaining sterility. When every milliliter represents significant value, even small losses during fill & finish can have a substantial impact on manufacturing efficiency and cost.

As a result, processes that are not specifically designed for small-batch production may lead to unnecessary product waste. Maximizing product yield requires both minimizing losses and ensuring accurate filling. Low hold-up volumes, optimized fluid paths, and efficient product recovery help reduce waste throughout the process.

At the same time, high filling accuracy is essential to avoid product giveaway while ensuring consistent dosing. To address these challenges, SKAN relies on precise filling technologies combined with in-process controls (IPC) and weight verification.

Product preservation extends beyond yield alone. Sensitive biological products may be affected by excessive mechanical stress, unsuitable materials, or process conditions that compromise product quality.

Our expertise in equipment design, material selection, and handling strategies helps protect product integrity throughout the filling process, particularly for advanced therapies and other high-value biologics.

Conclusion

Small batches require a different approach

As therapies become increasingly targeted and valuable, successful fill & finish operations depend on more than throughput. Minimized product loss, sterility assurance, and manufacturing efficiency are becoming key factors in achieving efficient and compliant small-batch manufacturing.

  • Closed processes as a solution

    To achieve efficient and compliant small-batch manufacturing, closed processes such as the AT-Closed Vial® Technology offer a compelling solution. It minimizes product loss, reduces contamination risks, leverages single-use systems, can be used in an isolator, is scalable from manual to fully automated, and is easy to implement from the beginning of development.

    → Learn more

  • Choosing the right partner

    Drawing on decades of expertise in aseptic processing, containment, and fill & finish technologies, SKAN helps manufacturers address these challenges throughout the product lifecycle, from early development to commercial production.

Cellana L1 filling close-up.

FAQ

  • The FDA defines a batch as “a specific quantity of a drug or other material that is intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture.”

  • There is no universally accepted definition of a small or medium batch in pharmaceutical manufacturing. However, batches of up to approximately 5,000 units are generally considered small batches, particularly in clinical manufacturing, biologics, orphan drugs, and advanced therapies.

  • A small-batch fill & finish solution should be designed to address the specific challenges of low-volume manufacturing. Key considerations include minimizing product loss, ensuring a high level of sterility assurance, preserving product integrity, and providing the flexibility and efficiency required for frequent changeovers and diverse production needs. SKAN offers a range of solutions designed to meet these requirements.

Solutions for small-scale filling

Looking for small batch fill & finish solutions?

Reach out to our expert team for small-scale filling – together, we can find the best solution for your application and product.

Back to top